Reach Us +1-947-333-4405
Expression Of Cancer Stem-like Cell Markers In Papillary Thyroid Cancer: An Immunohistochemical Analysis | 98868
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Expression of cancer stem-like cell markers in papillary thyroid cancer: An immunohistochemical analysis

Joint Event on 33rd International Conference on Oncology Nursing and Cancer Care and 16th Asia Pacific Pathology Congress

Hye Min Kim

Yonsei University College of Medicine, South Korea

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C4-055

Purpose: Cancer stem-like cell markers are reported be related to the prognosis of various cancers. The aim of this study was to investigate the clinical significance of stem-like cell markers in papillary thyroid carcinoma (PTC). Methods: We constructed tissue microarrays with 386 PTC cases. The expression of cancer stem-like cell markers was estimated using immohistochemical (IHC) staining for CD24, CD15, CD166, CD44, and ALDH1A1. The scores of IHC staining was calculated by multiplying the proportion of stained cells and immunostaining intensity, and was defined positive when the final score was >10. Associations between the expression of cancer stem-like cell markers between the clinicopathologic parameters were evaluated. Disease progession was defined as those experiencing recurrence or distant metastasis. Results: Among the patients included, a total of 59 patients experienced recurrence or distant metastasis during the follow-up. The proportion of CD15, CD166, CD44, and ALDH1A1 expression were higher in PTC patients with disease progression than without (p=0.014, <0.001, = 0.019, and <0.001, respectively). In multivariate Cox-proportional hazard analysis, CD15 positivity, CD166 positivity, and ALDH1A1 positivity were an independent factor for shorter progression free survival (odds ratio: 2.113, 7.413, and 2.574, 95% CI: 1.253-3.564, 4.296-12.791, and 1.014-6.360, p = 0.005, <0.001, and =0.041, respectively) along with the presence of lymph node metastasis. Conclusion: Expression of cancer stem-like cell markers CD15, CD166, CD44, and ALDH1A1 in PTC was associated with shorter progression free survival. These findings suggest that cancer stem-like cell markers might provide useful information in predicting patient prognosis in PTC.

Hye Min Kim has completed her residency in the Department of Pathology in Severance Hospital, Seoul, South Korea in 2016, and achieved a PhD degree at the age of 30 in Yonsei University College of Medicine. From the year of 2016, she is in a fellowship program in the department of Pathology of Severance Hospital.

E-mail: [email protected]